| 5 -0.59 (-10.55%) | 10-24 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 6.44  |
1-year : | 7.49 |
| Resists | First : | 5.52 |
Second : | 6.41 |
| Pivot price | 5.02 |
|||
| Supports | First : | 4.07 |
Second : | 3.39 |
| MAs | MA(5) : | 5.75 |
MA(20) : | 4.86 |
| MA(100) : | 4.18 |
MA(250) : | 0 | |
| MACD | MACD : | 0.2 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 59.5 |
D(3) : | 76.2 |
| RSI | RSI(14): 50.7 |
|||
| 52-week | High : | 8.78 | Low : | 2.33 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ AVR ] has closed above bottom band by 48.9%. Bollinger Bands are 60.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 5.59 - 5.63 | 5.63 - 5.65 |
| Low: | 4.86 - 4.9 | 4.9 - 4.93 |
| Close: | 4.95 - 5.01 | 5.01 - 5.05 |
Anteris Technologies Global Corp., a structural heart company, discovers, develops, and commercializes medical devices to enhance the quality of life for patients with aortic stenosis. Its lead product candidate is the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also devlops ADAPT anti-calcification tissue, an anti-calcification preparation that transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings, including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta. Anteris Technologies Global Corp. was incorporated in 1999 and is based in Toowong, Australia.
Fri, 24 Oct 2025
Anteris Technologies Announces Share Sale Agreement - TipRanks
Wed, 15 Oct 2025
Anteris Receives First European Regulatory Clearance To Commence DurAVR THV Global Pivotal Trial - TradingView
Wed, 15 Oct 2025
Anteris Receives First European Regulatory Clearance to - GlobeNewswire
Wed, 15 Oct 2025
Anteris receives Danish approval for heart valve pivotal trial - Investing.com
Wed, 15 Oct 2025
Anteris Technologies Prepares for Annual Stockholder Meeting - TipRanks
Fri, 10 Oct 2025
Investors bid Anteris Technologies Global (ASX:AVR) up AU$29m despite increasing losses YoY, taking five-year CAGR to 13% - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 0 (M) |
| Shares Float | 36 (M) |
| Held by Insiders | 3.036e+007 (%) |
| Held by Institutions | 0.2 (%) |
| Shares Short | 826 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -8.317e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -3 % |
| Return on Assets (ttm) | 379.2 % |
| Return on Equity (ttm) | -184.1 % |
| Qtrly Rev. Growth | 2.48e+006 % |
| Gross Profit (p.s.) | -6.48 |
| Sales Per Share | -1818.12 |
| EBITDA (p.s.) | 4.32353e+006 |
| Qtrly Earnings Growth | -3.1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -73 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 2.5 |
| Dividend | 0 |
| Forward Dividend | 1.58e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|